Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
July 27, 2021 — The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and…
TAG Celebrates TB Advocacy Award for Senior Policy Officer Elizabeth Lovinger
June 25, 2021 — TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.
In Memoriam – Marco Castro-Bojorquez
June 3, 2021 — We at Treatment Action Group (TAG) deeply mourn the loss of Marco Castro-Bojorquez, a visionary HIV and human rights activist, artist and filmmaker. Marco’s light shined brightly throughout his work and lifted up all around him.
TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies
June 3, 2021 — The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
May 10, 2021 — The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
May 6, 2021 — Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.
Landmark TB Trials Results Published in New England Journal of Medicine
May 6, 2021 — Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
February 16, 2021 — Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
February 1, 2021 — On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.